(Q37660900)

21 August 2017

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment (English)

1 reference

21 August 2017

0 references

Linda A Dimeglio

4

0 references

Mark Peakman

object named as

Mark Peakman

12

0 references

Robin Goland

6

object named as

Robin Goland

1 reference

21 August 2017

15

Desmond Schatz

1 reference

21 August 2017

18

Jeffrey P Krischer

1 reference

21 August 2017

8

Carla J Greenbaum

1 reference

21 August 2017

17

Darrell M Wilson

1 reference

21 August 2017

19

Jay S Skyler

1 reference

21 August 2017

3

Dorothy J Becker

1 reference

21 August 2017

Tihamer Orban

1

1 reference

21 August 2017

Brian Bundy

2

1 reference

21 August 2017

Stephen E Gitelman

5

1 reference

21 August 2017

Peter A Gottlieb

7

1 reference

21 August 2017

Jennifer B Marks

9

1 reference

21 August 2017

Roshanak Monzavi

10

1 reference

21 August 2017

Antoinette Moran

11

1 reference

21 August 2017

Philip Raskin

13

1 reference

21 August 2017

William E Russell

14

1 reference

21 August 2017

Diane K Wherrett

16

1 reference

21 August 2017

Type 1 Diabetes TrialNet Abatacept Study Group

20

1 reference

21 August 2017

language of work or name

English

0 references

publication date

2 December 2013

1 reference

21 August 2017

1 reference

21 August 2017

37

1 reference

21 August 2017

4

1 reference

21 August 2017

1069-1075

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

21 August 2017

start time

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Genetics, pathogenesis and clinical interventions in type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3964491

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24296850

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC13-0604

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

24296850

1 reference